Global registry for hip dysplasia in infants and children

A Prospective, Global Hip Dysplasia Registry with Follow-up to Skeletal Maturity: an Analysis of Risk Factors, Screening Practices and Treatment Outcomes

This study is creating a global registry to track infants and children with hip dysplasia to see which treatments work best and improve care for this condition.

Quick facts

• Study type: Observational
• Enrollment: 5000 (estimated)
• Ages: 1 Minute to 10 Years
• Sex: All
• Sponsor: University of British Columbia (Academic / other)
• Locations: 1 site (Vancouver, British Columbia)
• Trial ID: NCT04117685 on ClinicalTrials.gov

What this trial studies

This initiative aims to create a comprehensive, prospective international registry for infants and children diagnosed with developmental dysplasia of the hip (DDH). By standardizing treatment and management strategies, the registry seeks to identify best practices and improve clinical outcomes for this common pediatric hip condition. The study will collect data on patients aged 0 to 10 years who are referred for DDH screening or diagnosed with the condition, confirmed through imaging. The goal is to address inconsistencies in diagnosis and treatment that currently exist due to variations in practices and terminology.

Who should consider this trial

Good fit: Ideal candidates for this study are infants and children aged 0 to 10 years who are diagnosed with DDH or referred for screening due to specific risk factors.

Not a fit: Patients over 10 years of age at the time of initial diagnosis or those with known neuromuscular or congenital anomalies may not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could lead to improved diagnosis, treatment, and management of hip dysplasia, ultimately enhancing outcomes for affected infants and children.

How similar studies have performed: While there have been numerous studies on DDH, this registry approach is novel and aims to unify data collection and treatment practices across different regions.

Eligibility criteria

Inclusion Criteria:

* Between the ages of 0 and 10 years at time of initial diagnosis
* Referred for DDH screening due to specific risk factors OR diagnosed with DDH
* Diagnosis confirmed with appropriate ultrasonographic or radiographic imaging

Exclusion Criteria:

* Known or suspected neuromuscular, collagen, chromosomal or lower extremity congenital anomalies
* Teratologic hip dislocation (syndromic-associated dislocations)
* Over 10 years of age at initial diagnosis
* Received prior treatment for DDH without appropriate imaging or documentation

Where this trial is running

Vancouver, British Columbia

• British Columbia Children's Hospital — Vancouver, British Columbia, Canada (Recruiting)

Study contacts

• Principal investigator: Kishore Mulpuri, FRCSC — University of British Columbia
• Study coordinator: Emily K Schaeffer, PhD

Conditions Hip Dislocation, Congenital; Hip Dysplasia, Congenital, Nonsyndromic; Congenital Dysplasia of the Hip; Congenital Hip Dislocation; Congenital Hip Displacement; Congenital Hip Dysplasia; Dislocation of Hip, Congenital; Dislocation, Congenital Hip